(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 November 2015 (05.11.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/168468 A1

(51) International Patent Classification:
C07K 16/40 (2006.01) *C12N 9/64* (2006.01)

(21) International Application Number:
PCT/US2015/028641

(22) International Filing Date:
30 April 2015 (30.04.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/987,298 1 May 2014 (01.05.2014) US
62/076,372 6 November 2014 (06.11.2014) US

(71) Applicant *(for all designated States except AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)*: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080 (US).

(71) Applicant *(for AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR only)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors: **KELLEY, Robert F.**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **VAN LOOKEREN-CAMPAGNE, Menno**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **SCHEER, Justin M.**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **HASS, Philip E.**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **TESAR, Devin**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US).

(74) Agents: **YEUNG, Bonny G.** et al.; Genentech, Inc., 1 DNA Way, Mail Stop 49, South San Francisco, California 94080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTI-FACTOR D ANTIBODY VARIANTS AND USES THEREOF

VL Domain

```
WT          DIQVTQSPSSLSASVGDRVTITC[TSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQP
TM          DIQVTQSPSSLSASVGDRVTITC[T3TDIESDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQP
TM.D92E     DIQVTQSPSSLSASVGDRVTITC[TSTDIESDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQP
SIESD        DIQVTQSPSSLSASVGDRVTITC[TSTSIESDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQP
SIESD.N103S DIQVTQSPSSLSASVGDRVTITC[TSTSIESDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQP

WT          EDVATYYC[QSDSLPYTFGQGTKVEIK      (SEQ ID NO:3)
TM          EDVATYYC[QSDSLPYTFGQGTKVEIK      (SEQ ID NO:16)
TM.D92E     EDVATYYC[QSEESLPYTFGQGTKVEIK      (SEQ ID NO:18)
SIESD       EDVATYYC[QSDSLPYTFGQGTKVEIK      (SEQ ID NO:19)
SIESD.N103S EDVATYYC[QSDSLPYTFGQGTKVEIK      (SEQ ID NO:19)
```

VH Domain

```
WT          EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAY
TM          EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYAEDFKGRFVFSLDTSVSTAY
TM.D92E     EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYAEDFKGRFVFSLDTSVSTAY
SIESD       EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYAEDFKGRFVFSLDTSVSTAY
SIESD.N103S EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYAEDFKGRFVFSLDTSVSTAY

WT          LQISSLKAEDTAVYYC[RGGVNNWGQGTLVTVSS      (SEQ ID NO:4)
TM          LQISSLKAEDTAVYYC[RGGVNNWGQGTLVTVSS      (SEQ ID NO:17)
TM.D92E     LQISSLKAEDTAVYYC[RGGVNNWGQGTLVTVSS      (SEQ ID NO:17)
SIESD       LQISSLKAEDTAVYYC[RGGVNNWGQGTLVTVSS      (SEQ ID NO:17)
SIESD.N103S LQISSLKAEDTAVYYC[RGGVSNWGQGTLVTVSS      (SEQ ID NO:20)
```

FIG. 1B

(57) Abstract: The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.

WO 2015/168468 A1

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*